REG - Cambridge Cognition - Board Updates

Cambridge Cognition HoldingsAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251105:nRSE1925Ga&default-theme=true

RNS Number : 1925G  Cambridge Cognition Holdings PLC  05 November 2025

 

5 November 2025

Cambridge Cognition Holdings plc

("Cambridge Cognition", the "Company" or the "Group")

Board Updates

Cambridge Cognition Holdings plc (AIM: COG), the brain health software group
specialising in digital health products that advance brain health research and
treatment, announces the following changes to the board of directors.

CEO appointment

Rob Baker has been appointed as Chief Executive Officer with immediate effect.
Rob has served as the Company's Chief Operating Officer since September 2024
and joined the Board as Senior Executive Director on 28 August 2025.  Prior
to that, he was Chief of Product and Operations and originally joined the
Company as Head of Product in November 2022.

Before joining the Company, Rob held several senior roles at Amazon, including
leading large operational teams to scale Alexa voice technology improvements
and its privacy and security operations. In addition to his operational
expertise, Rob has significant sales and marketing experience having been
responsible for regional Amazon Echo device sales, device expansion and
large-scale e-commerce programs. Rob began his career at Siemens where he led
contract delivery within the Mobility Division before transitioning into
regional management roles within the Smart Infrastructure Division.

CFO appointment

Further to the announcement on 28 August 2025, Ronald Openshaw, who has served
as Chief Financial Officer and Head of Corporate Development since that date,
has been appointed to the Company's Board of Directors with immediate effect.
 Ronald has served as a consultant to the business advising on strategic
matters since 2022 and in August 2024 took over interim leadership of the
Company's finance function.

Ronald began his career at KPMG before becoming a senior healthcare investment
banker at both Jefferies and Panmure Gordon.  He has served as Chief
Executive Officer and/or Chief Financial Officer of several companies
including Simbec-Orion, a clinical research organisation, Plethora Solutions,
a speciality pharmaceutical company and Pharmagene/Asterand - a pioneer in the
use of human tissue in drug discovery and development.  He has also advised
numerous other companies in the life science and healthcare sector on
strategy, operational delivery and acquisitions and disposals.

Appointment of chair designate and future board changes

Further to the announcement that Dr Steven Powell would retire as
non-executive Chair of the board at the next annual general meeting the board
announces that Mr Nick Rodgers, who joined the Company as a non-executive
director in January 2024, will become Chair designate.  Nick is an adviser to
gene therapy company Santo Therapeutics and was until May 2024, Chair of
SEHTA, a health technology membership and networking organisation supporting
businesses in the health technology sector. Until 2023 Nick was Chair of
Destiny Pharma plc, a developer of novel anti-infective products and chair of
ZPN Energy Limited, a developer of battery storage technologies and systems.
 Previously, until 2016, Nick was chairman of Oxford BioMedica plc, a pioneer
of gene and cell therapy.

The Company expects to recruit a new, additional non-executive director to the
board and will make further announcements as the process proceeds.

Finally, the Company announces that Mr Alex Livingstone-Learmonth will not as
previously planned join the board.  Alex has informed the Company that he
intends to pursue other career opportunities outside Cambridge Cognition and
will leave the company in the new year.   Alongside Rob, Alex has
transformed the Company's commercial group since his appointment in early 2024
and the Company wishes to thank him for his valuable contribution.

 

Dr Steven Powell said:

"We are pleased to announce these changes to the Board of directors as the
Company continues to advance its growth and development. Following the
leadership changes introduced in autumn 2024, Rob has demonstrated strong
leadership qualities and we are excited to support his appointment as CEO.
Ronald joining the board is a natural and welcome progression having supported
the Company for several years.  I am pleased that Nick has become Chair
designate, bringing his many years of Board expertise and governance
knowledge."

 

 

FURTHER INFORMATION:

The following additional information is provided in accordance with Rule 17
and Schedule Two Paragraph (g) of the AIM Rules for Companies:

James Ronald Openshaw, aged 59, holds or has held the following directorships
in the last five years:

 Current directorships             Past directorships within the last five years
 Lucia Capital Consulting Limited  International Diagnostics Ltd

Mr Openshaw was a director of The Urology Company Limited at the time of its
creditors' voluntary liquidation on 17 September 2013.  Mr Openshaw was
declared bankrupt by The Insolvency Service on 26 April 2016. He was
subsequently discharged from bankruptcy, a statutory process, on 26 April
2017.

Save for the information disclosed above, there is no other information in
relation to Mr Openshaw that is required to be disclosed pursuant to Rule 17
and Schedule Two paragraph (g) of the AІM Rules for Companies.

 

Enquiries:

 

 Cambridge Cognition Holdings plc                  Tel: 01223 810700 

 Rob Baker, Chief Executive Officer                press@camcog.com (mailto:press@camcog.com)  

 Ronald Openshaw, Chief Financial Officer

 Panmure Liberum Limited (NOMAD and Joint Broker)  Tel: 020 7886 2968

 Will Goode / Freddy Crossley / Mark Rogers        (Corporate Finance)

 Rupert Dearden                                    (Corporate Broking)

 Dowgate Capital Limited (Joint Broker)            Tel: 020 3903 7715 

 David Poutney / Amber Higgs                        

 

Notes to Editors

 

About Cambridge Cognition

 

Cambridge Cognition is a brain health software group specialising in digital
health products that advance brain health research and treatment.

Built on rich, curated data and deep technical expertise we are building a
strong global brand with scalable technology that will support the rising
world demand for diagnosing and treating brain health. The Company creates
shareholder value through organic sales growth, strategic partnerships, joint
ventures, and spinouts.  The Company has identified four market sectors:

·      Clinical Studies for new pharmaceuticals;

·      Academic Research for scientists to understand CNS disorders;

·      Healthcare to provide physicians with cognitive assessments to
allow them to diagnose and treat patients; and,

·      Consumer Health & Wellness to provide individuals access to
accurate, reliable, and meaningful data to assess their cognitive health.

For further information, visit: www.cambridgecognition.com
(http://www.cambridgecognition.com/)

 

END

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAPKQBQFBDDCDK



            Copyright 2019 Regulatory News Service, all rights reserved